Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano (TO), Italy.
Cells. 2020 Jun 3;9(6):1396. doi: 10.3390/cells9061396.
Alemtuzumab is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. It is currently used as an immune reconstitution therapy in patients with relapsing-remitting multiple sclerosis. Alemtuzumab treatment is an intermittent infusion that induces long-term remission of Multiple Sclerosis also in the treatment-free period. After the robust T and B cell depletion induced by alemtuzumab, the immune system undergoes radical changes during its reconstitution. In this review, we will discuss the current knowledge on the reconstitution of the lymphocyte repertoire after alemtuzumab treatment and how it could affect the development of side effects, which led to its temporary suspension by the European Medical Agency.
阿仑单抗是一种单克隆抗体，可与 CD52 结合，CD52 是一种存在于成熟淋巴细胞表面的蛋白，但不存在于这些淋巴细胞衍生的干细胞中。它目前被用作复发性缓解型多发性硬化症患者的免疫重建治疗药物。阿仑单抗治疗是一种间歇性输注，可在无治疗期诱导多发性硬化症的长期缓解。在阿仑单抗诱导的强烈 T 细胞和 B 细胞耗竭后，免疫系统在重建过程中会发生根本性的变化。在这篇综述中，我们将讨论阿仑单抗治疗后淋巴细胞 repertoire 重建的最新知识，以及它如何影响副作用的发展，这导致了它被欧洲药品管理局暂时暂停使用。
